相关临床试验
104
23 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1887
进行中（未招募）
6
5.8%
已完成
44
42.3%
尚未招募
17
16.4%
招募中
27
26.0%
终止
3
2.9%
Unknown
6
5.8%
撤回
1
1.0%
暂无批准数据
- A new Landmark Perspective in Science marks the 50th anniversary of Robert C. Gallo's 1976 discovery of a human T-cell growth factor later named interleukin-2 (IL-2). - The discovery enabled long-term culture of human T cells, leading to identification of the first human retroviruses HTLV-1 and HTLV-2 and establishing human retrovirology. - The same capability proved critical to characterizing HIV as the cause of AIDS and to developing the HIV blood test, improving global blood supply safety. - IL-2 also underpinned cellular immunotherapy advances including tumor-infiltrating lymphocyte therapy and CAR-T cell therapy, with scientific exchange continuing in Venice in 2027.
- Moderna Therapeutics and the Institut Pasteur announced a long-term strategic research collaboration on February 3, 2015, to develop mRNA-based drugs and vaccines for infectious diseases. - Valera, a Moderna venture company focused on infectious disease prevention and treatment, will manage the collaboration and sponsor preclinical and clinical research programs at Institut Pasteur. - The partnership aims to combat known and emerging viral and bacterial diseases using Moderna's mRNA Therapeutics platform, which produces proteins and antibodies inside patient cells. - Moderna has also signed a Master Material Transfer Agreement granting Institut Pasteur researchers access to its preclinical manufacturing capabilities and R&D expertise for global health threats.
- Institut Pasteur Korea (IPK) and the Institut Pasteur (IP) signed a new General Framework Cooperation Agreement on 5 June 2026 during a joint international symposium in Seoul. - The agreement establishes a Scientific Liaison Committee, composed of three researchers from each institute, to institutionalize joint research and researcher exchange programs. - A parallel Joint Research Collaboration Workshop covered three thematic areas—Immunology, Vaccines and Viruses; Parasites and Bacteria; and Technology—to expand international collaborative research. - The partnership aims to jointly address future infectious disease threats, building on IPK's drug discovery and vaccine development capabilities against diseases including tuberculosis and COVID-19.
- Day Two of Bharat Innovates 2026 in Nice, France, facilitated more than 1,350 B2B meetings and over 50 collaboration agreements among global stakeholders. - More than 80 DeepTech startups pitched to 50-plus global investors from over 10 countries, with over 40 startups securing confirmed investor follow-up commitments. - Approximately USD 254.5 million in funding commitments and advanced-stage investments involving Bharat Innovates innovators have been announced across the summit. - The event, jointly inaugurated by Prime Minister Modi and President Macron, spans 13 key sectors including biotechnology, healthcare, and advanced manufacturing.
- A new €15.3 million EU-funded project, ACT-CHIK, will conduct a Phase Ib/III trial of the MV-CHIK chikungunya vaccine across Rwanda, Kenya, Nigeria, and Senegal, enrolling 940 participants including adults, adolescents, and children. - The MV-CHIK vaccine uses a measles virus Schwarz strain vector and has demonstrated satisfactory safety and immunogenicity in six prior Phase I/II trials involving approximately 600 adults. - The four-year initiative will prepare technology transfer of vaccine manufacturing to Institut Pasteur de Dakar, Africa's only WHO-prequalified vaccine manufacturer, supporting the African Union's goal of producing 60% of vaccines locally by 2040. - The international consortium spans seven partners across four continents, coordinated by Institut Pasteur, with the International Vaccine Institute serving as clinical trial sponsor.
- The University of Oxford, Université Paris Cité, Institut Pasteur, Diamond Light Source and Synchrotron SOLEIL signed a landmark agreement establishing the UK-France Strategic Interdisciplinary Alliance in Health and AI. - The Alliance will prioritize women's health (including endometriosis and pregnancy-related complications), pandemic preparedness, and antimicrobial resistance, combining AI, advanced imaging and data science. - Researchers will gain mutual access to national infrastructure such as the Diamond Light Source and Synchrotron SOLEIL, enabling molecular-level study of disease. - The UK government committed nearly £900,000 to link the Isambard-AI supercomputer with France's GENCI, plus £300,000 matched by €330,000 for early-career researcher mobility.
- Enodia Therapeutics raised €20.7 million in seed financing co-led by Elaia, Pfizer Ventures, and Bpifrance to develop small-molecule therapies for targeted protein degradation. - The company's proprietary platform uses machine learning to selectively modulate the SEC61 translocon, intervening at the point of protein synthesis rather than after proteins are fully formed. - Enodia plans to advance its lead program toward preclinical candidate selection within the next year, initially focusing on inflammatory and autoimmune diseases. - The company was founded by Argobio Studio based on pioneering research from Institut Pasteur and represents the third Argobio-founded company to achieve seed financing in 2025.
- Biofabri and Bharat Biotech have signed a technology transfer agreement to expand global access to MTBVAC, the only live, attenuated Mycobacterium TB vaccine currently in development. - The partnership will enable BBIL to manufacture and supply MTBVAC to more than 70 countries across Africa and Southeast Asia, regions with the highest TB burden. - MTBVAC has successfully completed Phase I and II clinical trials in India, demonstrating safety and immunogenicity, with a pivotal Phase III efficacy study expected to begin recruitment in Q1 2026. - The initiative aligns with WHO's Finance and Access Working Group Solution and India's TB Mukt Bharat initiative to combat tuberculosis through innovative vaccine development.
- Sensorion's Data Monitoring Committee found no safety concerns and approved continuation of the Audiogene Phase 1/2 trial for SENS-501 gene therapy targeting OTOF gene mutations. - Two of three patients in the second cohort demonstrated early hearing improvements by Month 3, with behavioral thresholds of approximately 60-70 dB HL at best-performing frequencies. - The trial targets infants aged 6-31 months with otoferlin-mediated congenital deafness, aiming to restore hearing during critical brain plasticity periods before cochlear implantation. - SENS-501 uses AAV viral vector technology to deliver functional OTOF gene copies directly to inner ear hair cells, representing a potential breakthrough for genetic hearing loss treatment.
- Researchers developed IgE-K, an experimental vaccine that provides year-long protection against anaphylaxis in mice by training the immune system to produce antibodies that block IgE, the key driver of allergic reactions. - The vaccine demonstrated remarkable efficacy in preventing deadly allergic reactions, with eight of nine unvaccinated control mice dying within 30 minutes of allergen exposure while all vaccinated mice survived with only mild symptoms. - Unlike current treatments like omalizumab that require injections every two weeks, the vaccine maintained high levels of protective antibodies for up to 52 weeks after immunization. - The vaccine showed no adverse effects and preserved the immune system's ability to fight parasites, addressing key safety concerns for potential human applications.
